Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine Blood Test Gets FDA Approval as CDx for Pfizer's Braftovi in Colorectal Cancer

NEW YORK – Foundation Medicine said Friday that it has received approval from the US Food and Drug Administration for its FoundationOne Liquid CDx assay as a companion diagnostic to Pfizer's Braftovi (encorafenib) in combination with cetuximab in for patients with metastatic colorectal cancer.

The test is now officially approved to identify adult patients harboring a BRAF V600E alteration, which makes them eligible for this targeted therapy and chemotherapy combination. Foundation said that its assay, a comprehensive next-generation sequencing panel, is the only test of its kind to receive CDx approval in this setting. According to the company, the Braftovi-cetuximab combination is also the first and only FDA-approved targeted therapy regimen for adults with BRAF V600E-mutated metastatic colorectal cancer after receiving prior therapies.

FoundationOne Liquid CDx analyzes more than 300 cancer-related genes and has netted FDA approval for several companion diagnostic indications in non-small cell lung cancer, breast cancer, colorectal cancer, and pan-cancer settings.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.